“Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Relapsed/Refractory Acute Myeloid Leukemia Market.
The Relapsed/Refractory Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Relapsed/Refractory Acute Myeloid Leukemia and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Relapsed/Refractory Acute Myeloid Leukemia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Relapsed/refractory acute myeloid leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Learn How the Ongoing Clinical & Commercial Activities will Affect the Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Segment @
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Therapeutics Landscape
There are approx. 50+ key companies developing therapies for Relapsed/refractory acute myeloid leukemia (AML). Currently, Ascentage Pharma is leading the therapeutics market with its Relapsed/refractory acute myeloid leukemia (AML) drug candidates in the most advanced stage of clinical development.
The Leading Players in the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Therapeutics Market Include
-
Ascentage Pharma
-
Cullinan Oncology
-
Kronos Bio
-
Maxinovel Pharmaceuticals
-
AB Science
-
CicloMed
-
Karyopharm Therapeutics
-
Antengene Corporation
-
GlycoMimetics
-
Servier
-
Novartis
-
ImmunoGen
And Many Others
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Therapies Covered in the Report Include
-
APG-2575: Ascentage Pharma
-
CLN 049: Cullinan Oncology
-
Lanraplenib: Kronos Bio
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Relapsed/Refractory Acute Myeloid Leukemia Current Treatment Patterns
4. Relapsed/Refractory Acute Myeloid Leukemia – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Relapsed/Refractory Acute Myeloid Leukemia Late Stage Products (Phase-III)
7. Relapsed/Refractory Acute Myeloid Leukemia Mid-Stage Products (Phase-II)
8. Relapsed/Refractory Acute Myeloid Leukemia Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Relapsed/Refractory Acute Myeloid Leukemia Discontinued Products
13. Relapsed/Refractory Acute Myeloid Leukemia Product Profiles
14. Key Companies in the Relapsed/Refractory Acute Myeloid Leukemia Market
15. Key Products in the Relapsed/Refractory Acute Myeloid Leukemia Therapeutics Segment
16. Dormant and Discontinued Products
17. Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs
18. Relapsed/Refractory Acute Myeloid Leukemia Future Perspectives
19. Relapsed/Refractory Acute Myeloid Leukemia Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to explore the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/